Press Release | August 12, 2021 | Investing, Drug Discovery, Orphan & Rare Diseases, Rare Diseases, Policy & Regulatory, Medicare Part B, Medicare Part D, Cost & Value of Biopharmaceuticals, Drug Pricing Blue Print
President Joe Biden today announced a slew of drug pricing reforms, including changes that would radically alter the widely successful Medicare program for seniors and people with disabilities.
Rich Masters, BIO’s Chief Public Affairs and Advocacy Officer, made the following remarks about the plan…